Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Voglibose
Cat. No.:
0225LY-0712
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Voglibose is an N-substituted valiolamine derivative that effectively inhibits alpha-glucosidases to manage hyperglycemia and its associated complications.
Synonym:
83480-29-9; (1S,2S,3R,4S,5S)-5-((1,3-dihydroxypropan-2-yl)amino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetraol; 3,4-Dideoxy-4-((2-hydroxy-1-(hydroxymethyl)ethyl)amino)-2-C-(hydroxymethyl)-D-epi-inositol; (1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol
CAS No.:
83480-29-9
Compound CID:
444020
Formula:
C10H21NO7
Formula Weight:
267.28
Specification
Relative Density:
1.58 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Voglibose can be used in diabetes research to examine the inhibition of alpha-glucosidase and its impact on postprandial glucose levels.
Library Information
Target:
α-Glucosidase
Receptor:
α-Glucosidase
Pathways:
Metabolism
Plate Number:
AOCL-10
Plate Location:
b9
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
100 mg/mL; 374.14 mM
Water Max Solubility:
26.7 mg/mL; 99.9 mM
ALogP:
-4.083
HBA_Count:
0
HBD_Count:
7
Rotatable Bond:
5
